
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
3. Medtronic’s Resolute stent meets Abbott’s Xience in “real world” patients

Medtronic’s Resolute drug-eluting stent proved equal to Abbott’s Xience DES in a "real-world" study of patients with complex lesions, according to results from the Twente trial.
2. J&J ditches DePuy trauma business ahead of Synthes merger

Biomet signed a binding offer to acquire the DePuy Orthopaedics global trauma business from Johnson & Johnson for $280 million in cash, in a deal aimed at appeasing European regulators over the health care giant’s proposed $21.3 billion Synthes buyout.
1. Medical device tax tab now at $30.5B

The medical device tax will raise 50% more than the $20 billion the government said was needed to pay for med-tech’s share of health care reform, with official government estimates pegging the total tab over 10 years at $30.5 billion.